Amgen Analyst Likes Diversified Business, Remains Patient Until MariTide Obesity Data

What happened

Amgen reported third-quarter sales of $10.365 billion, up 8%, with product sales growth led by higher volume; 17 products each delivered at least double-digit sales growth. It raised fiscal 2026 adjusted earnings-per-share and sales guidance, while RBC said more MariTide obesity data would not arrive until 2027.

Confirmed

Global impact / market context

Higher sales and raised guidance indicate stronger expected revenue and adjusted earnings, which can support investors’ view of Amgen’s business outlook. However, the article says RBC wants more MariTide data to assess Amgen’s position in obesity treatment, leaving that potential contribution uncertain until 2027.

Analyst inference

The article describes Amgen shares as near their 52-week high after results beat Wall Street’s expectations, suggesting recent performance already reflects some optimism. The analyst’s wait for MariTide data points to a separate future question about competitive positioning, not a confirmed near-term revenue driver.

Analyst inference

What to watch

1. Amgen’s next reported results can show whether sales growth and the raised fiscal 2026 guidance are being sustained across its broad product portfolio. Analyst inference
2. RBC said it is eager for more MariTide data to understand Amgen’s place in obesity treatment, but expects that data only in 2027. Confirmed
3. Investors can compare later sales growth across Amgen’s products with its guidance; weaker growth could make the higher forecast harder to achieve. Analyst inference

Evidence

• Original source link unavailable